Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd Unit 450, Houston, TX, 77030, USA.
Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd Unit 1484, Houston, TX, 77030, USA.
Curr Oncol Rep. 2021 Mar 14;23(4):41. doi: 10.1007/s11912-021-01026-w.
Desmoid fibromatosis (DF) is a locally aggressive clonal neoplasm with locally aggressive behavior and no metastatic potential. Historical treatment of DF has consisted primarily of up-front surgery when feasible. In recent years, recognition that DF can spontaneously stabilize or involute has allowed for many patients to be managed with watchful waiting rather than intervention. This review is intended to review recent developments in the treatment of DF.
Recent studies have demonstrated prospectively that patients with DF often have improvement in their lesions without intervention, enabling an initial period of surveillance as a standard option for patients with mild symptoms. Given the lengthening list of effective systemic treatments, including sorafenib, pazopanib, and experimental agents, there has been a less reliance on local therapies for those patients who require treatment. For patients with DF that require treatment, there is a growing list of options that includes radiation therapy (RT), percutaneous ablation, and a growing list of systemic agents with favorable toxicity profiles.
硬纤维瘤病（DF）是一种局部侵袭性克隆性肿瘤，具有局部侵袭性，无转移潜能。DF 的历史治疗主要包括在可行时进行前期手术。近年来，人们认识到 DF 可以自发稳定或消退，因此许多患者可以通过观察等待而不是干预来进行治疗。本综述旨在回顾 DF 治疗的最新进展。
最近的研究前瞻性地表明，DF 患者的病变经常无需干预即可改善，从而使监测作为轻症患者的标准选择成为可能。鉴于越来越多有效的系统治疗方法，包括索拉非尼、帕唑帕尼和实验性药物，对于需要治疗的患者，对局部治疗的依赖程度降低。对于需要治疗的 DF 患者，有越来越多的选择，包括放射治疗（RT）、经皮消融以及一系列具有良好毒性特征的系统药物。
